Printer Friendly

ADVANCED TISSUE SCIENCES' DERMAGRAFT(TM) STUDIES PRESENTED AT BURN CONFERENCE

 ADVANCED TISSUE SCIENCES' DERMAGRAFT(TM) STUDIES
 PRESENTED AT BURN CONFERENCE
 LA JOLLA, Calif., Feb. 18 /PRNewswire/ -- Advanced Tissue Sciences Inc. (NASDAQ-NMS: ATISA) announced that two scientific presentations on Dermagraft -- the company's living dermal replacement product -- were given at the Sixth Maui Burn Conference this month. The presenters were John F. Hansbrough, M.D., director of the Regional Burn Unit at the University of California, San Diego Medical Center, and Ron Cohen, M.D., the company's vice president of medical affairs.
 Dr. Hansbrough noted that Dermagraft has successfully vascularized, facilitated basement membrane formation and epithelialized in both preclinical and clinical studies, indicating the product's potential to facilitate wound closure. Dr. Hansbrough reported that more than 70 patients have been enrolled to date in a multicenter clinical trial under an Investigational Device Exemption.
 Dr. Cohen reported on updated characterization studies which showed Dermagraft to be physiologically similar to human dermis. He presented evidence that Dermagraft contains naturally secreted matrix components such as collagen, fibronectin and a number of growth factors, all of which are known to be important in the wound healing process.
 Dermagraft is now being tested at 12 burn centers nationwide and the company had received Food and Drug Administration approval to expand testing to include up to 24 centers. The company is also conducting a clinical trial of Dermagraft for the treatment of chronic venous skin ulcers at three leading wound care centers. Initial results of the burn clinical trials were presented at the International Symposium on Wound Healing and Wound Management in Chicago last October.
 Advanced Tissue Sciences is engaged in the growth of human tissue outside the body. The company is developing its proprietary three- dimensional culture system for potential therapeutic and laboratory applications.
 -0- 2/18/92
 /CONTACT: Alana B. Wheeler of Advanced Tissue Sciences, 619-450-5714/
 (ATISA) CO: Advanced Tissue Sciences Inc. ST: California IN: MTC SU:


KJ-CH -- SD004 -- 9974 02/18/92 13:11 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1992
Words:320
Previous Article:CUCOS ANNOUNCES SECOND QUARTER EARNINGS FOR FISCAL 1992
Next Article:DISNEY ANNOUNCES ACTIONS AT ANNUAL MEETING
Topics:


Related Articles
ADVANCED TISSUE SCIENCES FILES TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DIABETIC AND DECUBITUS ULCERS
ADVANCED TISSUE SCIENCES RECEIVES APPROVAL TO EXPAND DERMAGRAFT(TM) CLINICAL TRIALS TO DECUBITUS AND DIABETIC ULCERS
ADVANCED TISSUE SCIENCES AND CELL GENESYS TO COLLABORATE IN DEVELOPING A UNIVERSAL 'FULL-THICKNESS' SKIN TRANSPLANT PRODUCT
ADVANCED TISSUE SCIENCES ANNOUNCES INTERIM ANALYSIS SHOWS DERMAGRAFT(TM) MEETING CLINICAL TRIAL OBJECTIVES IN DIABETIC FOOT ULCERS
Advanced Tissue Sciences Announces Third Quarter Results
Advanced Tissue Sciences - Dermagraft Clinical Performance
Advanced Tissue Sciences Provides Dermagraft(R) Clinical Update
Advanced Tissue Sciences and Smith & Nephew Expand Dermagraft(R) Joint Venture
Advanced Tissue Sciences Announces Further Expansion of Dermagraft Joint Venture
Advanced Tissue Sciences Announces Second Quarter Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters